FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 28 3 2020
medline: 15 7 2020
entrez: 28 3 2020
Statut: ppublish

Résumé

Recent studies showed that FVIIa (factor VIIa), upon binding to EPCR (endothelial cell protein C receptor), elicits endothelial barrier stabilization and anti-inflammatory effects via activation of PAR (protease-activated receptor)-1-mediated signaling. It is unknown whether FVIIa induces PAR1-dependent cytoprotective signaling through cleavage of PAR1 at the canonical site or a noncanonical site, similar to that of APC (activated protein C). Approach and Results: Mouse strains carrying homozygous R41Q (canonical site) or R46Q (noncanonical site) point mutations in PAR1 (QQ41-PAR1 and QQ46-PAR1 mice) were used to investigate in vivo mechanism of PAR1-dependent pharmacological beneficial effects of FVIIa. Administration of FVIIa reduced lipopolysaccharide-induced inflammation, barrier permeability, and VEGF (vascular endothelial cell growth factor)-induced barrier disruption in wild-type (WT) and QQ46-PAR1 mice but not in QQ41-PAR1 mice. In vitro signaling studies performed with brain endothelial cells isolated from WT, QQ41-PAR1, and QQ46-PAR1 mice showed that FVIIa activation of Akt (protein kinase B) in endothelial cells required R41 cleavage site in PAR1. Our studies showed that FVIIa cleaved endogenous PAR1 in endothelial cells, and FVIIa-cleaved PAR1 was readily internalized, unlike APC-cleaved PAR1 that remained on the cell surface. Additional studies showed that pretreatment of endothelial cells with FVIIa reduced subsequent thrombin-induced signaling. This process was dependent on β-arrestin1. Our results indicate that in vivo pharmacological benefits of FVIIa in mice arise from PAR1-dependent biased signaling following the cleavage of PAR1 at the canonical R41 site. The mechanism of FVIIa-induced cytoprotective signaling is distinctly different from that of APC. Our data provide another layer of complexity of biased agonism of PAR1 and signaling diversity.

Identifiants

pubmed: 32212848
doi: 10.1161/ATVBAHA.120.314244
pmc: PMC7405933
mid: NIHMS1577737
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Endotoxins 0
Receptor, PAR-1 0
endotoxin, Escherichia coli 67924-63-4
Factor VIIa EC 3.4.21.21

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1275-1288

Subventions

Organisme : NHLBI NIH HHS
ID : R37 HL052246
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL052246
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL107483
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL124055
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142975
Pays : United States

Références

J Biol Chem. 2005 Apr 1;280(13):13122-8
pubmed: 15665002
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD005011
pubmed: 22419303
Blood. 2015 May 7;125(19):2898-907
pubmed: 25824691
Blood Coagul Fibrinolysis. 2005 Jun;16(4):297-9
pubmed: 15870551
J Blood Med. 2019 Sep 18;10:335-340
pubmed: 31572039
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):E1372-80
pubmed: 22106258
J Cell Sci. 2004 May 15;117(Pt 12):2427-9
pubmed: 15159447
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6393-7
pubmed: 19332793
J Biol Chem. 2000 Jun 2;275(22):17201-10
pubmed: 10748214
J Thromb Haemost. 2012 Aug;10(8):1675-84
pubmed: 22712885
Blood. 2016 Oct 6;128(14):1884-1893
pubmed: 27561318
Blood. 2004 Dec 15;104(13):3858-64
pubmed: 15328151
Blood. 2018 May 24;131(21):2379-2392
pubmed: 29669778
Blood. 2012 Dec 20;120(26):5237-46
pubmed: 23149848
J Biol Chem. 2016 Apr 22;291(17):8969-77
pubmed: 26984408
Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L43-54
pubmed: 12788788
J Biol Chem. 1994 Jan 28;269(4):2943-52
pubmed: 7507931
J Thromb Haemost. 2005 Aug;3(8):1800-14
pubmed: 16102047
Front Endocrinol (Lausanne). 2014 May 13;5:67
pubmed: 24860547
Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S147-52
pubmed: 9819047
Stroke. 2010 Jan;41(1):48-53
pubmed: 19959538
Blood. 2007 Apr 15;109(8):3161-72
pubmed: 17110453
Thromb Haemost. 2014 Nov;112(5):876-82
pubmed: 24990498
Blood. 2006 May 15;107(10):3912-21
pubmed: 16434493
Thromb Haemost. 2009 Apr;101(4):724-33
pubmed: 19350118
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2867-72
pubmed: 17299037
Cochrane Database Syst Rev. 2017 Sep 25;9:CD011441
pubmed: 28944952
J Thromb Haemost. 2014 May;12(5):690-700
pubmed: 24977291
Curr Opin Hematol. 2018 May;25(3):219-226
pubmed: 29461258
Blood. 2011 Mar 17;117(11):3199-208
pubmed: 21252088
Curr Surg. 2003 Jul-Aug;60(4):423-7
pubmed: 14972234
Blood. 2018 Mar 15;131(11):1163-1171
pubmed: 29343482
J Cell Sci. 2002 Feb 1;115(Pt 3):455-65
pubmed: 11861753
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
N Engl J Med. 2010 Nov 4;363(19):1791-800
pubmed: 21047223
Blood. 2008 Mar 1;111(5):2667-73
pubmed: 18089851
Blood. 2007 Dec 1;110(12):3909-16
pubmed: 17823308
J Biol Chem. 2007 Apr 20;282(16):11849-57
pubmed: 17327234
Crit Care Med. 2004 May;32(5 Suppl):S293-7
pubmed: 15118533

Auteurs

Vijay Kondreddy (V)

From the Department of Cellular and Molecular Biology, The University of Texas Health Science Center, Tyler (V.K., U.R.P., L.V.M.R.).

Usha R Pendurthi (UR)

From the Department of Cellular and Molecular Biology, The University of Texas Health Science Center, Tyler (V.K., U.R.P., L.V.M.R.).

Xiao Xu (X)

Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA (X.X., J.H.G.).

John H Griffin (JH)

Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA (X.X., J.H.G.).

L Vijaya Mohan Rao (LVM)

From the Department of Cellular and Molecular Biology, The University of Texas Health Science Center, Tyler (V.K., U.R.P., L.V.M.R.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH